Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Antibody drug conjugate

How published research underpinned a cancer therapy awareness campaign

Our client markets a product for Oral Mucositis (OM) - a side effect of cancer treatment - and wanted to better understand the disease and treatment challenges faced by both...

Inizio

How a hybrid approach delivered fast insights to feed into an oncology product’s adoption strategy

Our client wanted to quantify how ovarian cancer patients are managed prior to product launch, but also needed to understand why patients do or do not receive key diagnostic tests...

Inizio

Oncology experience & expertise

Did you know 25% of our business is in Oncology?

Inizio

- PMLiVE

Shire offloads oncology unit to Servier for $2.4bn

The French drugmaker will also acquire Oncaspar and Onivyde as part of the deal

- PMLiVE

Beyond caring: learning from the unsung advocates in cancer care

Macmillan Cancer Support estimates that there are currently around 1.5 million carers caring for someone who has cancer in the UK. Broadly, carers in and outside cancer contribute around £132...

- PMLiVE

AbbVie’s upadacitinib aces phase III trial

Arthritis drug outperformed both placebo and Humira in the study

Biogen Idec building

Settlement clears path for Biogen, Samsung’s Humira biosimilar

Agreement could see Europe access Imraldi as early as October this year

How scenario testing helped assess demand for a brand launch in the fragmented NSCLC market

Our client was developing a new drug aimed at first line NSCLC patients. Ahead of its launch they wanted to assess likely uptake in an already fragmented market space led...

Inizio

- PMLiVE

AbbVie slumps on trial results for would-be blockbuster Rova-T

The pharma group saw its shares plummet after the news broke

Research conducted by Research Partnership published in leading medical journal

Findings from a study conducted by Research Partnership have recently been published in the ‘Supportive Care in Cancer’ journal

Inizio

Biogen Idec building

Biogen and AbbVie pull MS drug Zinbryta from the market

Potential risks of liver damage and immune-related conditions have been reported

AstraZeneca AZ

CHMP backs AZ’s Lynparza for ovarian cancer maintenance

Studies show that the drug reduced risk of disease progression

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links